Bicycle Therapeutics (BCYC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Bicycle Therapeutics (BCYC) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.13 of bullish evidence against -0.47 bearish.

Bicycle Therapeutics last closed at $3.89, +2.10% on the session.

Against the IVW growth benchmark the position is +1.30% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for BCYC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Bicycle Therapeutics in the 22nd percentile on return on equity, where 100 is best.

Bicycle Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $266.67M.

StockMap tracks Bicycle Therapeutics as the 219th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Bicycle Therapeutics ranks 321st of 381 in the group, against a group median of -0.08.